Last reviewed · How we verify

ION582 — Competitive Intelligence Brief

ION582 (ION582) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antisense oligonucleotide; ApoB inhibitor. Area: Cardiovascular.

phase 3 Antisense oligonucleotide; ApoB inhibitor Apolipoprotein B (ApoB) mRNA Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ION582 (ION582) — Ionis Pharmaceuticals, Inc.. ION582 is an antisense oligonucleotide that reduces production of apolipoprotein B (ApoB) to lower LDL cholesterol levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ION582 TARGET ION582 Ionis Pharmaceuticals, Inc. phase 3 Antisense oligonucleotide; ApoB inhibitor Apolipoprotein B (ApoB) mRNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antisense oligonucleotide; ApoB inhibitor class)

  1. Ionis Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ION582 — Competitive Intelligence Brief. https://druglandscape.com/ci/ion582. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: